As the Director of Product Management for High Growth Markets at Cepheid, Pierre Turpin leverages his extensive expertise in cell and molecular biology to drive innovation and enhance diagnostic solutions in underserved regions. With over 15 years of experience in research use only (RUO), in...
As the Director of Product Management for High Growth Markets at Cepheid, Pierre Turpin leverages his extensive expertise in cell and molecular biology to drive innovation and enhance diagnostic solutions in underserved regions. With over 15 years of experience in research use only (RUO), in vitro diagnostics (IVD), and medical devices, Pierre is recognized for his strategic thinking and deep technical knowledge. His role focuses on portfolio and launch excellence management across diverse markets, including Asia-Pacific (APAC), the Commonwealth of Independent States (CIS), Latin America (LATAM), and the Middle East and Africa (MEA).
Pierre is particularly dedicated to advancing tuberculosis (TB) and HIV diagnostics, working to bring these critical tests closer to patients in low- and middle-income countries. His leadership in product launch planning and execution has resulted in successful rollouts of innovative systems, software, and connectivity solutions that address the unique challenges faced in these regions. By integrating voice of the customer (VoC) insights into product development, Pierre ensures that Cepheid’s offerings not only meet regulatory standards but also align with the needs of healthcare providers and patients alike.
His core competencies in portfolio planning, go-to-market strategy, and digital transformation enable him to navigate the complexities of the healthcare landscape effectively. Pierre's collaborative approach fosters cross-functional team leadership, driving strategic alliances that enhance Cepheid's impact in the global health arena. Through his commitment to improving patient outcomes and his passion for innovation, Pierre Turpin continues to shape the future of diagnostics in high-growth markets.
